Retinal Pigment Epithelium Safety Study for Patients in B4711001
NCT03102138 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 10
Last updated 2024-11-22
Summary
This is a safety follow-up study. Patients enrolled in B4711001 will be followed for a further 4 years with regular visits to assess safety.
Conditions
- Age Related Macular Degeneration
Sponsors & Collaborators
-
Moorfields Eye Hospital NHS Foundation Trust
lead OTHER
Principal Investigators
-
Lyndon da Cruz · Moorfields Eye Hospital NHS Foundation Trust
Eligibility
- Min Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-04-16
- Primary Completion
- 2027-05-30
- Completion
- 2028-06-30
Countries
- United Kingdom
Study Locations
More Related Trials
-
Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD
NCT02463344 ·Status: COMPLETED
-
Treatment of Age-related Macular Degeneration by Fetal Retinal Pigment Epithelial Cells Transplantation
NCT02868424 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration
NCT01344993 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Treatment of Dry Age Related Macular Degeneration Disease With Retinal Pigment Epithelium Derived From Human Embryonic Stem Cells
NCT03046407 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)
NCT01670162 ·Status: UNKNOWN ·Phase: PHASE4
-
Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Macular Degeneration Diseases
NCT02749734 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration
NCT01089517 ·Status: COMPLETED ·Phase: PHASE2
-
A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration
NCT01678872 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Autologous Bone Marrow-Derived CD34+, CD133+, and CD271+ Stem Cell Transplantation for Retinitis Pigmentosa
NCT02709876 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy
NCT01345006 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
NCT05230537 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Safety Study of RPE65 Gene Therapy to Treat Leber Congenital Amaurosis
NCT00643747 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
NCT04770545 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
NCT07174726 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene
NCT03328130 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Production of iPSC Derived RPE Cells for Transplantation in AMD
NCT02464956 ·Status: COMPLETED
-
Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients
NCT02445612 ·Status: COMPLETED
-
Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function
NCT00972374 ·Status: COMPLETED ·Phase: PHASE2
-
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD
NCT02461771 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)
NCT00511706 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)
NCT01469832 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa
NCT05874310 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration
NCT04895293 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)
NCT07185841 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Long-term Follow up Study of EXG102-031 in Participants With wAMD
NCT06859515 ·Status: RECRUITING